Tozorakimab for Viral Lung Infection Requiring Oxygen
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3,527 (estimated)
- Sponsor
- AstraZeneca · Industry
This trial is looking for adults who are hospitalized with a viral lung infection and need extra oxygen. Participants will receive treatment with tozorakimab along with their usual care to see if it helps prevent worsening conditions.
You may be able to join if
- I am at least 18 years old.
- I am hospitalized with a viral lung infection.
- I need supplemental oxygen due to low blood oxygen levels.
You may not be able to join if
- I have a fungal or parasitic lung infection.
- I have a lung abscess or evidence of septic shock.
- My low blood oxygen is due to a non-infectious cause.
- I am currently on a ventilator or ECMO.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Loading trial locations…
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT